Collaboration with Mary Tyler Moore Vision Initiative Collaboration with Mary Tyler Moore Vision Initiative Boehringer Ingelheim joins forces with Mary Tyler Moore Vision Initiative to combat vision loss from diabetes
collaboration-Yale collaboration-Yale Yale-Boehringer Ingelheim Biomedical Data Science Fellowship Program Seeks to Attract Top Researchers from Around the World
Moving towards a rabies-free Southeast Asia Moving towards a rabies-free Southeast Asia Boehringer Ingelheim, in collaboration with Eco-Business, has published a comprehensive whitepaper to stop rabies.
Translating Human Pharma Science into Animal Health Innovation Translating Human Pharma Science into Animal Health Innovation Megan Grether shares her perspectives on the importance of translating human pharma science to accelerate innovation in animal health
Partnering Approach Video 2023 Partnering Approach Video 2023 Our Animal Health Business Development & Licensing team talks about Boehringer Ingelheim’s unique partnering approach and spirit of collaboration.
Partnering in Central Nervous System Diseases Partnering in Central Nervous System Diseases We are looking for new early-science collaborations. Join our expanding community of innovation partners in central nervous system diseases.
Partnership to Develop Urea Cycle Disorders Therapy Partnership to Develop Urea Cycle Disorders Therapy Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders
It’s Your Heart. Protect It. The Podcast. It’s Your Heart. Protect It. The Podcast. In season 2, we hear from a range of experts to explore further how the interconnected systems call for collaboration and approach to care.
Boehringer biopharmaceuticals China receives approval supply EU and US Boehringer biopharmaceuticals China receives approval supply EU and US Boehringer Ingelheim Biopharmaceuticals China receives approval for supply of EU and US markets
Open Innovation at Boehringer Ingelheim Open Innovation at Boehringer Ingelheim Learn more about how we’re working across the innovation community to advance research and accelerate the development of new medicines
Partnership for new liver disease treatments with Ribo Partnership for new liver disease treatments with Ribo Boehringer Ingelheim partners with Ribo to develop new treatments for people with liver diseases
AUROBAC's Strategy & Pipeline Against Severe Infections & Resistance AUROBAC's Strategy & Pipeline Against Severe Infections & Resistance AUROBAC THERAPEUTICS presents strategy and growing pipeline to tackle severe infections and antimicrobial resistance
BI_X_Shanghai BI_X_Shanghai Boehringer Ingelheim opens a second branch of its digital lab in Shanghai
New Partnership to Develop Gene Therapy for Cystic Fibrosis New Partnership to Develop Gene Therapy for Cystic Fibrosis Boehringer Ingelheim steps into the field of gene therapy with experienced partners to jointly develop first gene therapy for cystic fibrosis
Partnership Boehringer Ingelheim Lifebit health data Partnership Boehringer Ingelheim Lifebit health data Boehringer Ingelheim and Lifebit announce partnership to capture transformational value of health data
Soaring to save lives Soaring to save lives Tackling health disparities through drone delivery of vaccines animals and livestock living in underserved communities
PRRS vaccine celebrates 25 years in Europe PRRS vaccine celebrates 25 years in Europe Boehringer Ingelheim celebrates 25 years to combat PRRS in Europe
Winners of BVDzero Scholarship Programme Winners of BVDzero Scholarship Programme Boehringer Ingelheim announces winners of BVDzero Scholarship Programme
Boehringer and ZEISS partnership eye diseases Boehringer and ZEISS partnership eye diseases Boehringer Ingelheim and ZEISS join forces to early detect eye diseases and prevent vision loss
S&P Animal Health Partnering Oct 2023 S&P Animal Health Partnering Oct 2023 Interview by S&P Global with Megan Grether, discussing Boehringer Ingelheim Animal Health Partnering’s ambition and approach
Phase II trial results in people living with obesity or overweight Phase II trial results in people living with obesity or overweight Phase II trial with BI 456906 met primary endpoint after 46 weeks of treatment, representing an important advancement of Boehringer Ingelheim’s cardio-renal-metabolic focus areas
Supply Chain Scholarship for Cowtribe Supply Chain Scholarship for Cowtribe A supply chain course we sponsored boosted the career of Latifa Saaka
Second cancer immunotherapy partnership with 3T Bio Second cancer immunotherapy partnership with 3T Bio Second cancer immunotherapy partnership with 3T Bio
Uniting to stop rabies: a global and local endeavor Uniting to stop rabies: a global and local endeavor By collaborating together, we can stop rabies. Read how we are breaking down barriers through the power of partnerships to fight this deadly disease